Common diseases such as coronary heart disease (CHD) are complex in etiology. The interaction of genetic susceptibility with lifestyle factors may play a prominent role. However, gene-lifestyle interactions for CHD have been difficult to identify. Here, we investigate interaction of smoking behavior, a potent lifestyle factor, with genotypes that have been shown to associate with CHD risk.
C oronary heart disease (CHD) is a complex disorder resulting from the interplay of lifestyle and genetic factors; 1 ,2 yet, gene-lifestyle interactions for CHD have been difficult to identify. Cigarette smoking is one of the strongest lifestyle risk factors for CHD, but the underlying molecular mechanisms of CHD in humans who smoke remain uncertain. [3] [4] [5] Cigarette smoking accounts for one-fifth of all CHD events globally and is responsible for ≈1.6 million deaths attributable to CHD annually. 6 Genome-wide association studies (GWAS) have improved our understanding on the genetic predisposition to both CHD and smoking behavior. [7] [8] [9] [10] Joint or interactive effects of genetic variation and smoking behavior in the etiology of CHD, however, remain poorly understood. GWAS can provide new opportunities to investigate gene-smoking interactions.
We hypothesized that genetic predisposition to CHD is modified by cigarette smoking at loci discovered by GWAS to be associated with either CHD or smoking behavior. We conducted a focused experiment at 50 maineffect loci (45 for CHD and 5 for smoking behavior) using genetic data and information on smoking behavior in 60 919 CHD cases and 80 243 controls from 29 different studies. We report novel findings on gene-smoking interactions in CHD.
METHODS

Summary of Study Design
All studies participating in the CARDIoGRAMplusC4D consortium (Coronary Artery Disease Genome-Wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics) [7] [8] [9] that had information available on smoking status, CHD risk, and genotypes at the 50 CHD and smoking behavior-associated loci were invited to participate. The current study had 5 interrelated components (online-only Data Supplement Figure I ). First, as part of the quality control, we investigated the association of smoking status with CHD risk within each study. Second, we performed an updated analysis of all the single-nucleotide polymorphisms (SNPs) (±50 kb) at the 45 established CHD loci to identify the variant with the strongest CHD association in our study population at each established CHD locus. Effect estimates from each study in association with CHD risk were obtained and pooled to identify the strongest CHD-associated variant (lead variant), in our study population. Third, we investigated gene-smoking interactions at these 45 CHD loci and at 5 loci related to smoking behavior. Fourth, for loci demonstrating differential CHD associations by smoking status, we mapped the interaction region, examined linkage disequilibrium (LD) across the region, and performed conditional analyses to identify independent genetic signals. Last, for loci exhibiting gene-smoking interaction in CHD, we assessed expression quantitative trait loci (eQTL) data for association of variants with expression of local genes in available data sets and examined expression of these genes in multiple cell types that play prominent roles in smoking-CHD pathobiology.
Harmonization of Phenotypes and Genotypes
Summary-level estimates for each study were shared via a secure FTP site. We used ever-smoking as a primary exposure, and data were harmonized by uniformly characterizing participants in each study into 2 categories, ever-smokers and never-smokers. Ever-smokers were defined as those who had smoked >100 cigarettes in a lifetime. For case-control studies, information on ever-smoking status collected at the time of enrollment was used for the current analyses; whereas for prospective cohort studies, information on smoking status obtained at the baseline visit was used for the current investigation. CHD was defined based on evidence from angiography or history of verified myocardial infarction (MI), percutaneous coronary interventions, or coronary artery bypass grafting as published in CARDIoGRAMplusC4D projects. [7] [8] [9] Genotype data generated through GWAS (directly genotyped or imputed) or cardio-metabochip (directly genotyped only) arrays were obtained from each study, and all genetic data were aligned using the build-37 reference panel. Imputed SNPs were removed if they had any of the following: (i) a minor allele frequency of <1%; (ii) info score of <0.90; or (iii) confidence score of <0.90. For each study, GWAS data were imputed using the Phase II CEU HapMap reference population.
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Standard quality control criteria were applied by each participating study, as described previously. 7 All participating studies
Clinical Perspective
What Is New?
• Using data on 60 919 coronary heart disease (CHD) cases and 80 243 controls, this study conducted gene-lifestyle interaction analyses to investigate effect modification by smoking behavior at established CHD-and smoking-related loci.
• Cardioprotective effects associated with allelic variation at the ADAMTS7 locus were attenuated by 60% in people who smoked tobacco in comparison with those who did not smoke.
• Allelic variation at ADAMTS7 associated with reduced CHD risk was associated with reduced ADAMTS7 expression in human aortic endothelial cells and lymphoblastoid cell lines.
• Exposure of human coronary artery smooth muscle cells to cigarette smoke extract led to induction of ADAMTS7.
What Are the Clinical Implications?
• These human genomic data provide new insights into potential mechanisms of CHD in cigarette smokers.
• Findings from this study also point toward the directional impact of the ADAMTS7 locus on CHD.
• ADAMTS7 and its substrates have a specific role in cigarette smoking-related CHD.
• Inhibition of ADAMTS7 is a novel potential therapeutic strategy for CHD that may have particular benefits in individuals who smoke cigarettes.
in the CARDIoGRAMplusC4D consortium were approved by their locally relevant institutional review boards, and all participants gave written informed consent before their enrollment in each study.
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Statistical Analysis
Gene-Smoking Interaction Analyses
Initial quality control and association of established CHD loci with CHD risk
As part of an initial quality control, effect estimates from each study were obtained for ever-smoking status and CHD risk by using a case-control logistic regression model adjusted for age and sex. Each participating study also assessed and, if needed, controlled for population stratification by including principal components as covariates in the regression model as described earlier. [7] [8] [9] To identify variant(s) with the most significant association with CHD risk at established CHD loci in our study population, logistic regression analyses were conducted by each participating study for all the SNPs flanking (±50 kb) the lead variant previously reported at each CHD locus. Effect estimates and standard errors were obtained and meta-analyzed using a fixed-effects inverse variance approach. All lead variants identified through these analyses were further investigated for gene-smoking interactions in CHD. One lead variant per locus was selected for primary gene-smoking interaction analyses.
Investigation of the APOE locus
Although APOE has been recently established as a GWAS locus, 7 previous studies before GWAS suggested that CHD risk is higher among carriers of the ε4 allele at the APOE locus in smokers than in nonsmokers. [12] [13] [14] Because the ε2, ε3, and ε4 alleles at the APOE locus are not captured perfectly by the GWAS platform, we specifically conducted genotyping for rs429358 and rs7412 variants to capture the three epsilon (ε) alleles in 13 822 participants (including 7286 first-onset MI cases) in the PROMIS study (Pakistan Risk of Myocardial Infarction Study). 15 
Gene-smoking interaction analyses at CHD and smoking loci
To assess gene-smoking interactions, analyses were conducted within each study, adjusted for age, sex, and other study specific covariates (eg, principal components), and variants were analyzed in association with CHD separately in ever-smokers and never-smokers. Results from the 2 groups were then used to test for interaction within each study. For the 50 variants, an interaction test statistic was calculated within each study using the following equation as adapted from Teslovich et al where β n and β e are the β-coefficients for the SNP in neversmokers and ever-smokers, respectively, SEn and SEe are the standard errors for the log-odds ratios (ORs) estimated for never-smokers and ever-smokers, respectively. Study-specific interaction β(s) and standard error(s) were calculated within each study and were pooled across studies using a fixedeffects meta-analysis. Interaction analyses were declared to be significant at a P value of <1.0×10 -3 (Bonferroni correction for 50 tests).
Conditional analyses on chr.15q25.1
At chr.15q25.1, we observed 2 variants exhibiting genesmoking interactions for CHD. The proximity of these 2 signals raised the possibility that the observed interactions may represent a single interaction locus across the entire region. To investigate this possibility, we undertook conditional analyses using an approximate conditional and joint analyses approach, also known as Genome-wide Complex Trait Analysis, as described previously. [17] [18] [19] [20] [21] [22] In brief, this method leverages summary-level statistics from a meta-analysis and uses LD corrections between SNPs estimated from a reference sample. Such an approach has been shown to yield results similar to those obtained from conditional analyses conducted on individual participant data and has been successfully implemented in several other studies that have fine-mapped loci for other complex traits. [17] [18] [19] [20] [21] [22] Using this approach, we first conducted separate conditional analyses at the chr.15q25.1 locus to identify main-effect variant(s) independently associated with CHD and smoking behavior, respectively. We used the meta-analyzed data for CHD main effects in the CARDIoGRAMplus4D consortium to identify SNPs independently associated with CHD risk, and we used the genetic meta-analysis data from the Tobacco and Genetics Consortium in 140 000 participants to identify variants independently associated with smoking behavior. We then estimated the effects of these independent variants on CHD risk stratified by smoking status and mutually adjusted the effects of these variants for each other.
Analysis of eQTLs and Regulatory Features at the chr15q25.1 Gene-Smoking Interaction Locus
eQTL analyses
We mined publicly available databases to identify genotyperelated expression differences (eQTLs) in ADAMTS7 and the CHRNB4-A3-A5 gene cluster to understand the directionality of the association of these genes with CHD and smoking behavior. Specifically, we investigated data available from the GTEx consortium, 23 the HapMap consortium (restricted to European populations),` and the Multiple Tissue Human Expression Resource (MuTHER). 24 We also analyzed expression data in 147 donor human aortic endothelial cell (HAoEC) lines. 25 We used a nominal P value of 0.002 to account for multiple testing involved in the eQTL analyses.
Regulatory features of the chr. 15q25.1 region
Data from ENCODE (Encyclopedia of DNA Elements) 26 were explored as described in online-only Data Supplement Methods. Chromatin immunoprecipitation sequencing (ChIPseq) experiments were performed on confluent cultured human coronary artery smooth muscle cells (HCASMC) (Cell Applications 350-05a and Lonza CC-2583; cultured in SmGM-2 BulletKit media; Lonza) as described.
27 TCF21 (Abcam ab49475), Jun (Santa Cruz Biotechnology sc-1694), JunD (Santa Cruz Biotechnology sc-74), and CEBP (Santa Cruz Biotechnology sc-150) transcription factor binding was interrogated, and H3K27ac data were acquired using the same ChIP protocol with an anti-H3K27ac antibody (Abcam; ab4729). Reads were aligned to the human genome (GRCh37p13) using STAR. 
Analyses of ADAMTS7 and CHRNB4-A3-A5 Gene Expression in Vascular Cells and Tissues
ADAMTS7 and CHRNB4-A3-A5 Gene Expression in Vascular Cells
ADAMTS7 and CHRNB4-A3-A5 Gene Expression in Response to Cigarette Smoke Extract
HCASMCs were grown to confluence, and cigarette smoke extract experiments were performed at passage 7. Cigarette smoke extract was custom prepared by Arista Laboratories. In brief, the condensate was generated by smoking Marlboro Red King Size Hard Pack cigarettes on an analytic smoke machine under International Organization for Standardization smoking conditions. The smoke condensate was collected on 92-mm filter pads and extracted from each pad in dimethyl sulfoxide by shaking to obtain a solution of ≈20 mg/mL final concentration of the total particulate matter. Serum-starved (24 hours) HCASMC were treated with 0.5% or 1.0% cigarette smoke extract (v/v) for 4, 12, and 24 hours in serum-reduced conditions (0.5% fetal bovine serum in Dulbecco modified Eagle medium). Details on RNA preparation and quantitative polymerase chain reaction are provided in online-only Data Supplement Methods.
RESULTS
Description of the Participating Studies
Of the 37 studies participating in the CARDIoGRAMplusC4D consortium, information on ever-smoking was available in 30 studies, yielding a total sample size of 60 919 CHD cases and 80 243 controls. All studies recruited participants of European ancestry, except PROMIS (South Asian), 15 LOLIPOP (South Asian) 29 and FGENTCARD (Lebanese). 30 Number of CHD cases and controls and percentages that were ever-smokers are provided in onlineonly Data Supplement Table I . As expected, in all the participating studies, association of ever-smoking status with CHD risk was directionally consistent with an increased risk of CHD (online-only Data Supplement Figure II ).
New Variants Associated With CHD at Established Loci
Online-only Data Supplement Figure III and online-only Data Supplement Table II present effect estimates for the association with CHD for (i) the most significant variant that we identified at known CHD loci in the current CARDIoGRAMplusC4D consortium analysis, and for (ii) the top SNP previously reported at each of these established CHD loci, as well. Of the 45 established CHD loci, we identified 32 for which we discovered a more statistically significant SNP in association with CHD risk in our data set than the previously reported top variant. All of these 32 SNPs were in moderate to high LD (r 2 >0.6) with the previously published variants. [7] [8] [9] In our primary gene-smoking interaction analyses, at each of the CHD loci, therefore, we used the SNP with the most significant CHD association (online-only Data Supplement Figure III and online-only Data Supplement Table II) . Because the smoking behavior phenotype (captured as cigarettes per day [CPD]) was not available in all CARDIoGRAMplusC4D studies, we used the top variant previously reported for CPD 10 at each locus (online-only Data Supplement Figure IV) .
Analyses of the APOE Locus
The effect of rs6857, the lead CHD variant at the APOE locus, was similar in ever-smokers in comparison with never-smokers (online-only Data Supplement Table III ). Specifically, the CHD OR for the T allele at rs6857 was found to be 1.10 (P=7.93×10 -4 ) in never-smokers (12 159 CHD cases and 22 932 controls) which was quantitatively similar to the CHD OR of 1.09 (P=8.68×10 -5 ) observed in ever-smokers (23 753 CHD cases and 24 019 controls) (interaction P value=0.76) (online-only Data Supplement Figure VA) . Investigation in the PROMIS study of the APOE ε genotypes yielded consistent findings; the OR for CHD among ε4 carriers in never-smokers was 1.13 in comparison with the CHD OR of 1.07 observed in ever-smokers (interaction P value=0.82) (online-only Data Supplement Figure VA) .
Novel Gene-Smoking Interaction Effects on CHD at Chromosome 15q25.1
Of the 50 loci, we identified effect-modification by eversmoking status on CHD risk for the lead variants at 2 distinct loci, rs7178051, in proximity of ADAMTS7 (an established CHD locus), and rs1051730, in proximity of CHRNB4-A3-A5 (an established smoking behavior locus) (online-only Data Supplement Table III) . Although associated with different traits and located in distinct LD blocks, these 2 variants reside ≈224 kb apart on chr.15q25.1 and are in weak LD (r 2 =0.22), raising the question of whether these 2 variants exhibiting gene-smoking interactions on CHD are independent of each other.
At the ADAMTS7 CHD locus, the T allele at the rs7178051 variant was found to be more strongly and inversely associated with CHD risk in never-smokers (OR, 0.88; P=7.02×10 -16 ) in comparison with a much weaker effect in ever-smokers (OR, 0.95; P=8.64×10 4 ) (P value of interaction=8.57×10 -5 ) (Table) . Thus, the protective impact of the rs7178051 T allele observed in never-smokers was halved in people who smoked (Figure 1) . This difference is not related to power differences within strata because, for this variant, there were fewer data available in the never-smoking group (21 232 CHD cases and 38 713 controls) than in the ever-smoking group (39 585 CHD cases and 40 749 controls). There was no substantial evidence of heterogeneity for the interaction β across the participating studies (P value for the χ 2 test of heterogeneity=0.06; I 2 =31.0%; τ-squared [τ 2 =0]). We further conducted sensitivity analyses using a random-effects model; the results remained unchanged and the interaction β remained significant (online-only Data Supplement Figure VB) . Although the frequency of rs7178051 was 39% in Europeans in comparison with 28% in South Asians, further analyses stratified by ancestry (ie, European versus non-Europeans) showed similar results (online-only Data Supplement Figure VC) . Other variants discovered through prior CHD GWAS at the AD-AMTS7 locus (eg, rs7173743, rs4380028, rs3825807) were in moderate to high LD (r 2 >0.50) with rs7178051 and were also found to display a similar pattern of genesmoking interaction effects (Table) .
At the CHRNB4-A3-A5 smoking locus, the A allele at the rs1051730 variant had an inverse trend (not significant after adjustment) of association with CHD in never-smokers (OR, 0.96; P=1.56×10
-2 ) and a positive trend (not significant after adjustment) in ever-smokers (OR, 1.03; P=1.53×10 -2 ) (P value of interaction=2.37×10 -4 ) (Table and online-only Data  Supplement Table III) . For this variant, data on 20 559 CHD cases and 38 198 controls were available in the never-smoking group, whereas 38 923 CHD cases and 40 371 controls were available in the ever-smoking group. Similar gene-smoking interaction patterns were observed for other variants (eg, rs2036527 and rs8034191) that had been previously reported for CPD behavior at the CHRNB4-A3-A5 gene cluster (Table) .
Further interrogation of the chr15q21.1 region encompassing rs7178051 and rs1051730 across 3 distinct LD blocks (Figure 1 ) revealed multiple additional variants for which we observed gene-smoking interactions in CHD (Table and Figure 1 ). Indeed, several SNPs (eg, rs7178051, rs10083696, rs7176187, rs6495335, rs4887077) had genome-wide significant associations with CHD in never-smokers but had weaker and less significant associations with CHD in ever-smokers (Figure 1 ). Alleles clustered specifically around AD- AMTS7 rather than at the CHRNB4-A3-A5 genes appear to be protective of CHD in never-smokers, but have attenuated protective effects in ever-smokers ( Figure 2 ).
Conditional Analyses
To investigate the possibility that the 2 separate genesmoking interactions at chr.15q25.1 might represent a single interaction locus across the entire region, we undertook an approximate conditional and joint analyses 17-22 using summary data derived from CARDIoGRAMplus4D for CHD and from the Tobacco and Genetics Consortium for smoking behavior. In addition to rs7178051, we identified 1 other variant, rs11072794 in low LD with rs7178051 (r 2 =0.20) that was associated independently with CHD ( Figure 3A ; red triangles) ( Figure 3B and online-only Data Supplement Figure VIB ; red triangles). We also confirmed 2 variants (rs1051730 and rs684513) located in 2 different LD blocks that were independently associated with smoking behavior in the Tobacco and Genetics Consortium data 10 ( Figure 3D and online-only Data Supplement Figure VIB ; gray circles).
In analyses of the CHD variants, both rs7178051 and rs11072794 remained strongly associated with CHD after adjusting for the top CPD variants (rs1051730 and rs684513) ( Figure 3D , red triangles), whereas their weak association with CPD was lost after adjusting for the top CPD variants ( Figure 3D ; gray circles); eg, the P value for rs7178051 association with CPD was 1×10 -5 in unadjusted analyses, but attenuated to 0.55 after adjusting for rs1051730 and rs684513. In analyses of the CPD variants, both rs1051730 and rs684513 remained strongly associated with CPD after adjusting for the top CHD variants (rs7178051 and rs11072794) ( Figure 3B , gray circles), whereas their weak association with CHD was lost after adjusting for the top CHD variants ( Figure 3B, red triangles) . As expected, conditional analyses that included all 4 of these variants resulted in a null association of the region with both CHD and CPD (online-only Data Supplement Figure VIB) . To underscore the validity of the conditional approach using summary data, we used individual participant data from an expanded PROMIS sample involving 9025 MI cases and 8506 controls. We found that the OR conferred by Each superscript number (1-21) refers to the physical location of the variant in Figure 1 . CHD indicates coronary heart disease; LD, linkage disequilibrium; NPR, not a previously reported variant with disease risk; SB, smoking behavior; and SE, standard error.
*Lead variant in association with CHD in our data set. †Lead variant in association with SB. Table. Continued allelic variation at rs7178051 remained associated with MI risk independent of the 2 CPD variants (rs1051730 and rs684513) and rs11072794 (the second CHD SNP) (online-only Data Supplement Figure VIC) . Conversely, the apparent effect of allelic variation at rs1051730 (the top CPD variant) on CHD risk was lost when we adjusted for the other 3 variants, rs7178051, rs11072794, and rs684513 (online-only Data Supplement Figure VIC) . Next, using summary-level data, we examined the association of each of these 4 variants with CHD risk separately in ever-smokers and never-smokers while mutually adjusting for the other 3 variants (Figure 4 and online-only Data Supplement Figure VII) . In these analyses, only allelic variation at rs7178051 was found to have independent genome-wide significant effects on CHD in never-smokers. rs7178051 was also the only one of these 4 variants with significant differences in the effect estimate for gene-CHD associations between the 2 smoking groups (P value for the χ 2 test of heterogeneity=5.4×10 -5 ) after adjusting for the effects of other variants (rs11072794, rs1051730, and rs684513). These conditional analyses suggest that (a) variants located near the ADAMTS7 gene but not CHRNB4-A3-A5 genes have independent effects on CHD, (b) a single independent gene-smoking interaction signal for CHD exists on chr.15q.25.1 that is localized at the ADAMTS7 CHD locus (marked by rs7178051), and (c) an apparent interaction signal observed at the nearby CHRNB4-A3-A5 CPD locus (marked by rs1051730) is not independent of the ADAMTS7 (rs7178051) interaction signal.
To assess the robustness of conditional analysis methodology that uses summary-level data (ie, Genome-wide Complex Trait Analysis), [17] [18] [19] [20] [21] [22] we conducted sensitivity analyses in the PROMIS data set (9025 MI cases and 8506 controls). We assessed the association of rs7178051 (top CHD SNP) and rs1051730 (top CPD SNP) after mutually adjusting for each other by conducting (i) standard logistic regression using individual participant data and (ii) summary-level data in PROMIS using the Genome-wide Complex Trait Analysis method (online-only Data Supplement Table IV ). The top CHD SNP was found associated with CHD risk in PROMIS independent of the top CPD variant using both the methods, in contrast, the effect on CHD of the top CPD SNP attenuated sharply when adjusted for the top CHD SNP; the effect estimates obtained using the 2 methods were very similar (online-only Data Supplement Table IV) .
Last, to further demonstrate that the gene-smoking interaction effect in CHD at rs7178051 is independent of the CHRNB4-A3-A5 CPD locus, we conducted sensitivity analyses in the PROMIS study by restricting our gene-lifestyle interaction analysis to subjects who do not carry the minor alleles of rs1051730 and rs684513 (the 2 SNPs associated with CPD) at the CHRNB4-A3-A5 locus. The T allele at the rs7178051 variant was associated with CHD only in never-smokers (OR, 0.88; P=0.01) in comparison with a weaker and nonsignificant association in ever-smokers (OR, 0.94; P=0.21) (online-only Data Supplement Table V) . The effect estimates obtained in each of the categories defined by smoking status in PROMIS were similar to the effect estimates obtained in our overall meta-analyses that used data in all participants (online-only Data Supplement Table V) .
Analysis of eQTLs and Regulatory Features at the chr15q25.1 Gene-Smoking Interaction Locus
We mined publicly available eQTL data from the HapMap consortium, 11 GTEx consortium, 23 and the MuTHER consortium, 24 and data from 147 HAoEC lines, 25 as well, to examine the association between mRNA expression of ADAMTS7 and CHRN genes with CHD, CPD, and gene-smoking interaction SNPs at the chr15q25.1 locus. SNP-mRNA associations with P<0.002 (correction for 20 tests) are presented ( Figure 5 ). The top 2 CHD variants (rs7178051, rs11072794) are associated with reduced ADAMTS7 expression (eg, rs11072794 P=6.01×10 -21 in MuTHER LCL, n=850; and rs7178051 P=0.0029 in HAoEC, n=147) but have no association with expression of CHRN genes in any cell or tissue examined. In contrast, the top 2 CPD variants (rs1051730 and rs684513) were associated with CHRN gene expression (eg, rs1051730 P=6.9×10 -7 for CHRNA5 in GTEx skeletal muscle and nerve tissue) but have no association with ADAMTS7 in these cells or tissues. These findings complement conditional analyses suggesting that gene-CHD and gene-smoking interaction effects on CHD are likely mediated by ADAMTS7, whereas the smoking behavior effect appears to be mediated through the CHRNA3-5 gene cluster.
In analysis of data from the ENCODE project 26 and for human aortic tissue in NIH Roadmap Epigenomics project, ADAMTS7 was associated with RNAseq reads and an active transcription mark, H3K36me3, whereas CHRN genes had low/absent RNAseq reads and were positive for repressive marks, H3K27me3 and H3K9me3 (onlineonly Data Supplement Figure VIII) . In HCASMC ChIPseq data, rs7178051, the top CHD and gene-smoking CHD interacting SNP, is located in a region with active regulatory marks H3K4me1 and H3K4me3, and a transcription factor binding site for TCF21, an important HCASMC transcription factor also associated with coronary artery disease, as well. This ChIPseq pattern was observed also in human aortic tissue ( Figure 6 ). These regulatory data suggest active transcription of ADAMTS7, but not CHRN genes, in vascular cells and aortic tissue and reveal that rs7178051, the lead gene-smoking CHD interaction SNP, overlaps active transcription marks and transcription factor binding regions in HCASMC.
ADAMTS7 and CHRNB4-A3-A5 Expression in Vascular Cells and Their Response to Cigarette Smoke Extract
To explore which genes at the chr15q25. 1-rs7173743; 2-rs10083696; 3-rs7176187; 4-rs7178051; 5-rs6495335; 6-rs4380028; 7-rs3825807; 8-rs3813565; 9-rs11638490; 10-rs11072794; 11-rs11072791; 12-rs922692; 13-rs11638372; 14-rs4887077; 15-rs12899135; 16-rs17487514; 17-rs1051730; 18-rs637137; 19-rs2036527; 20-rs10519203; 21-rs8034191. LD 1-3 indicate three separate linkage disequilibrium blocks in European ancestry at the chromosome 15q25.1 locus. Figure 1 . A, Regional association analyses at the chromosome 15q25.1 locus in association with CHD risk stratified by smoking status.
Association P values for genetic variants with CHD risk in never-smokers (green squares) and ever-smokers (red triangles). B, Longitudinal bars represent gene-smoking CHD interaction P values at the chromosome 15q25.1 locus; bars in blue are P values for variants listed in the Table and each variant has been assigned a unique identification number based on its physical location. C, LD blocks at the 15q25.1 locus visualized through HAPLOVIEW using LD estimates in the HapMAP-2 CEU reference population. CHD indicates coronary heart disease; and LD, linkage disequilibrium. expressed at a very low level for each of the genes in the CHRNB4-A3-A5 cluster in any of these cell types (onlineonly Data Supplement Figure IX) . Next, we explored the effect of cigarette smoke extract on gene expression in HCASMC, a cell type of particular relevance to vascular responses to cigarette smoke products, 31, 32 and to AD-AMTS7 vascular functions in atherosclerosis and CHD, as well. 33 In primary HCASMC, cigarette smoke extract exposure increased ADAMTS7 mRNA levels by >2-fold ( Figure 5 ), but did not affect expression of the CHRN genes (not shown). Thus, in contrast to CHRN genes, ADAMTS7 is both expressed and modulated by cigarette smoke extract in CHD-relevant vascular cells providing biological support for ADAMTS7, but not CHRN genes, in the gene-smoking interaction effect at chr15q25.1.
DISCUSSION
We conducted a gene-lifestyle interaction study at 50 loci associated with either CHD or smoking behavior and found evidence of effect modification of genotype-related CHD risk by smoking behavior at the chr.15q21.1 CHD locus. Specifically, we observed highly significant attenuation of the cardioprotective effects associated with alleles at this locus in people who smoked cigarettes. Conditional analyses identified an LD block located at the ADAMTS7 gene that accounted for both the main effect on CHD, and the gene-smoking interactions in CHD, as well. Data from expression and cell studies support our genetic analysis, suggesting that the underlying mechanism relates to genotype differences in the effect of smoking on expression of ADAMTS7 in vascular tissue.
Our findings have novel mechanistic and clinical implications. These human genomic data provide new insights into the mechanism of CHD in cigarette smokers. Identification of gene-smoking interaction at the chr15q21.1 locus suggests a specific role in smoking-related CHD for ADAMTS7 and its substrates, vascular matrix and vascular smooth muscle cell biology more broadly. Such Figure 2 . Several variants at chromosome 15q21.1 have stronger effects on CHD risk in never-smokers than in ever-smokers.
Variants with the strongest interaction P values are displayed. CHD indicates coronary heart disease; and LD, linkage disequilibrium.
insights can help to prioritize translational strategies for smoking-related CHD and present opportunities to study lifestyle interventions and pharmacological strategies to lower CHD in individuals who smoke cigarettes. Thus, inhibition of ADAMTS7 represents a novel potential therapeutic strategy for CHD that may have particular benefits in individuals who smoke cigarettes. All smokers should receive counseling for smoking cessation, yet such broad public health strategies have failed to reach or impact smoking behavior in a large portion of nicotineaddicted individuals. Our data provide a human genomic context for consideration of targeting specific genetically at-risk individuals via intensified preventive strategies and development of novel pharmacological treatments.
Our study also represents a realistic strategy for performing gene-lifestyle interaction studies using contemporary genetic data. We illustrate that identifying joint effects of genetic and lifestyle factors in CHD requires very large sample sizes, yet such analyses are biologically informative when studies are adequately powered. In this context, an important observation in our large sample is the lack of effect modification by smoking behavior on CHD at the APOE locus, a previously reported smoking interaction locus. [12] [13] [14] This finding is consistent with a recent meta-analysis that found no evidence of effect modification by smoking for APOE genotypes and CHD risk. 34 These studies raise concerns that most prior gene-lifestyle interaction studies in CHD have been prone to the same biases (ie, limited statistical power and false-positive associations) as candidate gene studies investigating main effects in the pre-GWAS era. The present study differs from previous studies by being much larger, and, more important, it includes genomic and functional follow-up data supporting the plausibility of the observed gene-lifestyle interaction.
ADAMTS7 (or the A disintegrin and metalloproteinase with thrombospondin motifs-7) is a member of the ADAMTS family of secreted zinc metalloproteases. 35, 36 We previously discovered and replicated genetic variation at the ADAMTS7 locus in association with coronary atherosclerosis and MI. [7] [8] [9] Both in vivo and in vitro studies suggest that ADAMTS7 modulates vascular smooth muscle cell phenotype switching and migration and that this may be mediated via cartilage oligomeric matrix protein or thrombospondin-1, 32, 33 ie, putative ADAMTS7 substrates expressed in vascular tissue. Genetic varia- Figure 3 . Stepwise conditional analysis of genetic variation at the chromosome 15q21.1 locus with CHD (red triangles) and smoking behavior (cigarettes per day, CPD; gray circles).
At the chromosome 15q21.1 locus, analyses adjusted for rs7178051 and rs11072794 completely attenuated the gene-CHD associations, whereas gene-smoking remained unchanged. Analyses adjusted for rs1051730 and rs684513 completely attenuated the gene-smoking associations, whereas gene-CHD effect remained unchanged. CHD indicates coronary heart disease. tion at ADAMTS7, however, has no relationship with traditional risk factors or mechanistic biomarkers; hence, the directional impact of ADAMTS7 expression on CHD risk and the underlying biological mechanisms have been unclear. 32 Our gene-smoking interaction analyses provide novel insights into the directional impact of the ADAMTS7 locus on CHD, the underlying mechanisms of CHD in smokers, and how such findings ultimately might translate toward achieving health benefits in society. Our human eQTL interrogations reveal that common alleles that relate to lower CHD risk at the ADAMTS7 locus are also associated with reduced ADAMTS7 expression, implying an atherogenic role of the gene. This is supported by our recent in vivo experimental studies; Adamts7 deficiency protected against diet-induced atherosclerosis in both the Ldlr -/-and ApoE -/-mouse models, reduced neointima formation following arterial injury, and decreased vascular smooth muscle cell migration in vitro. 33 In our smoking-stratified analyses, we observed the CHD protective effect that was attenuated in smokers. Thus, smoking exposure may overcome the genetic effect of protective alleles that act by reducing ADAMTS7 expression. Such a possibility is supported by our HCASMC data that reveal increased ADAMTS7 expression in HCASMC exposed to cigarette smoke extract. These human genome-smoking studies are the first to implicate a specific locus as causal in mediating increased risk of CHD in smokers. Additional translational studies are needed to establish the precise mechanisms of atheroprotection for alleles at the ADAMTS7 locus, how cigarette smoking impacts these genetic effects, and whether deletion or inhibition of AD-AMTS7 in vivo attenuates the specific acceleration of atherosclerosis conferred by cigarette smoking.
Strengths and limitations of our study merit consideration. This is a large study that conducted gene-smoking interaction analyses in CHD by using GWAS data. We observed substantial heterogeneity across study samples in our initial quality control analyses of eversmoking status with CHD risk. This is similar, however, to the heterogeneity reported in a recent meta-analysis that pooled risk ratios from all the past prospective studies with information on association of ever-smoking with incident CHD events. 5 We recognize that other smokingrelated phenotypes are important, eg, current smoking may have a more pronounced role than ever-smoking in plaque rupture and thrombosis in patients with MI. However, we were unable to distinguish between former versus current smokers within ever-smokers in our current analyses; furthermore, we were not able to analyze graded exposure to cigarette smoking such as pack-years. Given the use of multiple studies and meta-analyses of data, we used only 1 analytic approach to investigate gene-smoking interactions. This approach, however, was feasible and powerful in this large-scale consortium setting. Although we used a fixed-effects approach in our meta-analyses, a random-effects meta-analysis yielded qualitatively similar results. The lack of replication is partially offset by a large sample size, consistency across study cohorts and racial groups, and supplemental genomic and experimental evidence supporting biological plausibility. This approach is also consistent with recent recommendations 37 that favor use of a powerful discovery experiment using all data rather than reducing power by splitting an available data set for discovery and validation. Although our in vitro studies support a role for ADAMTS7 in the gene-smoking interaction, it will be important to confirm that Adamts7 deficiency protects against cigarette-smoke acceleration of atherosclerosis in rodent models.
Our interaction analyses, conditional analyses, eQTL interrogations, and cell studies suggest that ADAMTS7, but not the CHRNB4-A3-A5 gene cluster, is likely causal Figure 5 . A, ADAMTS7 and CHRNB4-A3-A5 mRNA levels were measured in HCASMC.
Cells were cultured to confluence, total RNA was extracted and cDNA generated. q-PCR was performed for ACTB, GAPDH, TBP, ADAMTS7, CHRNB4, CHRNA3, CHRNA5 (95°C 15 s, 60°C 1 min). Delta Cts were calculated as follows: (Ct ACTB + Ct GAPDH + Ct TBP )/3 -Ct TARGET GENE ). Fold changes are derived from delta Ct (dCt) based on formula fold change=2 -dCt
. B, Confluent HCASMC were exposed to cigarette smoke extract. Serum-starved (for 24 hours) confluent HCASMC were treated with 0.5% or 1.0% cigarette smoke extract (v/v) for 4, 12, and 24 hours in serum-reduced conditions (0.5% FBS in DMEM). Total RNA was extracted, cDNA generated preparation and q-PCR performed for ADAMTS7 by Taqman and normalized to GAPDH. The average Ct for ADAMTS7 at baseline was 28.25. Results were presented as means±SEM, and data were analyzed using Student t test. C, Expression and eQTL data from the GTEx consortium, the HapMap consortium (restricted to European populations), the Multiple Tissue Human Expression Resource (MuTHER), and in 147 donor HAoEC lines. Association of the independent lead variants identified in our conditional analyses with expression of ADAMTS7 and genes in the CHRNB4-A3-A5 cluster. A P value threshold of 0.002 was set to account for multiple testing involved in the eQTL analyses. DMEM indicates Dulbecco modified Eagle medium; FBS, fetal bovine serum; HAoEC, human aortic endothelial cells; HCASMC, human coronary artery smooth muscle cells; q-PCR, quantitative polymerase chain reaction; and SEM, standard error of the mean. at 15q21.1 for gene-smoking interaction effects in CHD. Yet, these analyses are not definitive. Although top interacting SNPs and CHD SNPs (eg, rs7178051) were associated with ADAMTS7, but not CHRNB4-A3-A5, expression in LCLs, large-scale eQTL data, and allele-specific expression data (eg, via RNA sequencing) are not available for vascular tissues, limiting causal inference. In our small human coronary artery endothelial cell data sets, however, we did find that alleles at rs7178051 associate with ADAMTS7 expression but not with any CHRNB4-A3-A5 genes, suggesting, at least in 1 vascular cell type, that the gene-smoking interaction is mediated via ADAMTS7.
CONCLUSIONS
We provide novel evidence for allelic variation exhibiting gene-smoking interaction in CHD at the chr.15q21.1 locus. The protective effect conferred by variation at this locus in never-smokers is markedly attenuated in people who are ever-smokers. Stepwise conditional analyses, gene expression data in vascular cells, eQTL interrogation, and cigarette smoke extract exposure in HCASMC suggest that ADAMTS7 accounts for both the genesmoking interaction in CHD and the CHD main effect on chr.15q21.1. Our findings reveal interactions of genetic variants and a key lifestyle determinant in the etiology of CHD, provide new insights into the potential mechanisms of CHD in cigarette smokers, and facilitate advances in precision medicine in relation to cigarette smoking-related CHD. Our work motivates future large-scale studies investigating joint effects of genes and lifestyle exoposures in CHD using existing complex-disease consortia data sets and genome-wide discovery approaches. This will provide opportunities to detect additional and novel loci displaying gene-lifestyle interactions revealing genet- Figure 6 . Genome browser view of regulatory features at rs7178051 on Chr15q21.1.
ChIP-seq experiments were performed on confluent HCASMC for TCF21, Jun, JunD, CEBP, and H3K4me1, H3K27me3, and H3K27ac. DNAaseI hypersensitivity data for human AoSMC were acquired from the ENCODE project. Human aortic tissue H3K4me1, H3K9me3, H3K27me3, and H3K36me3 ChIP-seq data were acquired from the NIH Roadmap Epigenomics Project. AoSMC indicates human aortic smooth muscle cells; ChIP, chromatin immunoprecipitation; HCASMC, human coronary artery smooth muscle cells; NIH, National Institutes of Health; and seq, sequencing.
